Collagen I Fibrous Substrates Modulate the Proliferation and Secretome of Estrogen Receptor-Positive Breast Tumor Cells in a Hormone-Restricted Microenvironment.


Journal

ACS biomaterials science & engineering
ISSN: 2373-9878
Titre abrégé: ACS Biomater Sci Eng
Pays: United States
ID NLM: 101654670

Informations de publication

Date de publication:
14 06 2021
Historique:
pubmed: 11 3 2021
medline: 22 6 2021
entrez: 10 3 2021
Statut: ppublish

Résumé

The fibril orientation of type I collagen has been shown to contribute to tumor invasion and metabolic changes. Yet, there is limited information about its impact on tumor cells' behavior in a restrictive growth environment. Restrictive growth environments are generated by the inhibition of a proliferation stimulus during therapy or as an inflammatory response to suppress tumor expansion. In this study, the impact of a type I collagen matrix orientation and fibrous architecture on cell proliferation and response to estrogen receptor (ER) therapy were examined using estrogen-dependent breast tumor cells (MCF-7 and T-47D) cultured in a hormone-restricted environment. The use of hormone-free culture media, as well as pharmacological inhibitors of ER, Tamoxifen, and Fulvestrant, were investigated as hormone restrictive conditions. Examination of cultures at 72 h showed that tumor cell proliferation was significantly stimulated (1.8-fold) in the absence of hormones on collagen fibrous substrates, but not on polycaprolactone fibrous substrates of equivalent orientation. ER inhibitors did not suppress cell proliferation on collagen fibrous substrates. The examination of reporter cells for ER signaling showed a lack of activity, thus confirming a shift toward an ER-independent proliferation mechanism. Examination of two selective inhibitors of α2β1 and α1β1 integrins showed that cell proliferation is suppressed in the presence of the α2β1 integrin inhibitor only, thereby indicating that the observed changes in tumor cell behavior are caused by a combination of integrin signaling and/or an intrinsic structural motif that is uniquely present in the collagen fibrils. Adjacent coculture studies on collagen substrates showed that tumor cells on collagen can stimulate the proliferation of cells on tissue culture plastic through soluble factors. The magnitude of this effect correlated with the increased surface anisotropy of the substrate. This sensing in fibril orientation was further supported by a differential expression pattern of secreted proteins that were identified on random and aligned orientation substrates. Overall, this study shows a new role for electrospun collagen I fibrous substrates by supporting a shift toward an ER-independent tumor cell proliferation mechanism in ER+ breast tumor cells.

Identifiants

pubmed: 33688723
doi: 10.1021/acsbiomaterials.0c01803
pmc: PMC8877809
mid: NIHMS1777603
doi:

Substances chimiques

Collagen Type I 0
Receptors, Estrogen 0
Fulvestrant 22X328QOC4

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2430-2443

Subventions

Organisme : NCI NIH HHS
ID : K01 CA188167
Pays : United States

Références

Matrix Biol. 1997 Mar;15(8-9):545-54
pubmed: 9138287
PLoS One. 2015 Apr 09;10(4):e0123312
pubmed: 25856378
Clin Cancer Res. 2002 Mar;8(3):878-84
pubmed: 11895922
Biomaterials. 2017 Jan;114:34-43
pubmed: 27838472
Am J Pathol. 2011 Mar;178(3):1221-32
pubmed: 21356373
World J Clin Oncol. 2014 Dec 10;5(5):908-20
pubmed: 25493229
Sci Rep. 2016 Sep 28;6:34094
pubmed: 27678304
Acta Biochim Biophys Sin (Shanghai). 2007 Aug;39(8):549-59
pubmed: 17687489
Biomaterials. 2011 Mar;32(8):2149-59
pubmed: 21167597
Langmuir. 2012 Jan 31;28(4):2028-34
pubmed: 22182057
Mater Sci Eng C Mater Biol Appl. 2019 Jan 1;94:108-116
pubmed: 30423689
Int J Oncol. 2017 Jun;50(6):2033-2042
pubmed: 28498390
Micron. 2011 Apr;42(3):283-9
pubmed: 21134761
Nat Rev Cancer. 2009 Sep;9(9):631-43
pubmed: 19701242
J Biol Chem. 2012 Dec 28;287(53):44694-702
pubmed: 23132859
Nat Commun. 2017 Nov 24;8(1):1770
pubmed: 29176665
Clin Cancer Res. 2003 Jan;9(1 Pt 2):447S-54S
pubmed: 12538499
Int J Mol Med. 2018 May;41(5):2573-2588
pubmed: 29484384
Prog Histochem Cytochem. 2002;37(1):3-54
pubmed: 11876085
Carcinogenesis. 2014 Aug;35(8):1671-9
pubmed: 24903340
Mol Cancer Ther. 2014 Aug;13(8):2050-61
pubmed: 24899686
Br J Pharmacol. 2006 Jan;147 Suppl 1:S269-76
pubmed: 16402113
F1000Res. 2018 Mar 5;7:274
pubmed: 29983921
Biomaterials. 2014 Aug;35(25):6954-63
pubmed: 24835043
J Mech Behav Biomed Mater. 2013 Jan;17:307-16
pubmed: 23122714
Lab Chip. 2018 Jan 30;18(3):451-462
pubmed: 29318250
BMC Med. 2006 Dec 26;4(1):38
pubmed: 17190588
J Cancer. 2016 Jun 25;7(10):1295-310
pubmed: 27390605
PLoS One. 2015 Jan 21;10(1):e0116891
pubmed: 25607819
Scanning. 2014 Jan-Feb;36(1):170-83
pubmed: 23878095
Nucleic Acids Res. 2009 Jan;37(Database issue):D603-10
pubmed: 18953024
Cancer Chemother Pharmacol. 2010 Feb;65(3):447-55
pubmed: 19543729
Cancer Lett. 2013 Dec 1;341(2):265-73
pubmed: 23962560
Anal Bioanal Chem. 2009 Oct;395(3):829-37
pubmed: 19685340
Biopolymers. 1988 Nov;27(11):1749-60
pubmed: 3233328
Biomed Res Int. 2014;2014:365867
pubmed: 24804215
Biomaterials. 2009 May;30(15):2956-65
pubmed: 19249094
J Biol Chem. 2013 Mar 15;288(11):7528-7535
pubmed: 23341452
Breast. 2018 Feb;37:134-141
pubmed: 29156385
Science. 2009 Nov 27;326(5957):1216-9
pubmed: 19965464
BMC Med. 2008 Apr 28;6:11
pubmed: 18442412
Biopolymers. 1975 May;14(5):937-57
pubmed: 1156652
PLoS One. 2012;7(3):e33248
pubmed: 22438903
Cancer Manag Res. 2018 Aug 30;10:3083-3099
pubmed: 30214302
Nat Med. 1999 Jun;5(6):662-8
pubmed: 10371505
Phys Med Biol. 2017 Jun 21;62(12):4756-4776
pubmed: 28520556
Eur J Radiol. 2013 Nov;82(11):e676-9
pubmed: 23932637
Biophys J. 2014 Dec 2;107(11):2546-58
pubmed: 25468334
Clin Cancer Res. 1996 Dec;2(12):2037-42
pubmed: 9816164
BMC Bioinformatics. 2011 Jan 26;12:35
pubmed: 21269502
Biomol Ther (Seoul). 2012 May;20(3):256-67
pubmed: 24130921
Biochem Biophys Rep. 2016 Jul;6:108-112
pubmed: 27092337
Oncogenesis. 2017 Jan 30;6(1):e295
pubmed: 28134933

Auteurs

Ana M Reyes-Ramos (AM)

Department of Chemical Engineering, University of Puerto Rico-Mayagüez, Call Box 9000, Mayagüez, Puerto Rico 00681-9000, United States.

Yasmín R Álvarez-García (YR)

Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.

Natalia Solodin (N)

Department of Oncology, McArdle Laboratories for Cancer Research and University of Wisconsin Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, 1111 Highland Avenue, Madison, Wisconsin 53705, United States.

Jorge Almodovar (J)

Ralph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, Arkansas 72701, United States.

Elaine T Alarid (ET)

Department of Oncology, McArdle Laboratories for Cancer Research and University of Wisconsin Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, 1111 Highland Avenue, Madison, Wisconsin 53705, United States.

Wandaliz Torres-Garcia (W)

Department of Industrial Engineering, University of Puerto Rico-Mayagüez, Call Box 9000, Mayagüez, Puerto Rico 00681-9000, United States.

Maribella Domenech (M)

Department of Chemical Engineering, University of Puerto Rico-Mayagüez, Call Box 9000, Mayagüez, Puerto Rico 00681-9000, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH